NCT02681978View on ClinicalTrials.gov

Ivabradine to Improve Endothelial Function in Patients With Coronary Artery Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Coronary Artery Disease
Interventions
DRUG

Ivabradine

Ivabradine 5 mg twice daily

DRUG

Standard medical therapy

Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions

Trial Locations (1)

00128

Campus Bio-Medico University, Rome

All Listed Sponsors
lead

Campus Bio-Medico University

OTHER

NCT02681978 - Ivabradine to Improve Endothelial Function in Patients With Coronary Artery Disease | Biotech Hunter | Biotech Hunter